CaleoBio is working to improve how new treatments are developed using human stem cell-based technology.
The company’s Organ-Dish platform is designed to better replicate human disease and help researchers develop safer, more effective therapies. CaleoBio received nearly $500,000 in Maryland state funding in 2024 to continue its work.
